Jesús Loarce
@JesusLoarce
Followers
876
Following
2K
Media
201
Statuses
1K
Rheumatology, Ramón y Cajal University Hospital. Interested in idiopathic inflammatory myopathy and interstitial lung diseases associated to CTD.
Joined March 2019
Tercer día de resúmenes #ACReview25 de @SEReumatologia que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 https://t.co/gDJ0Lbu7VM
0
7
22
Feliz y agradecida por haber compartido este #ACReview25 con un equipazo y una coordinación impecable. Un lujo trabajar con vosotros 💙@a_lois_ @montesa_maria @JesusLoarce @LuisCorTar @reumacia @SEReumatologia #ACR25
2
4
26
Segundo día de resúmenes #ACReview25 de @SEReumatologia que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 https://t.co/gDJ0LbuFLk
1
9
22
Primer día de resúmenes #ACReview25 de @SEReumatologia que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 https://t.co/gDJ0Lbu7VM
1
11
31
Espero veros a todos siguiendo el #ACR25 review 🇺🇸 de @SEReumatologia que tengo el gusto de coordinar Revisores TOP 🔝 - @RoxOsler ➡️ AR - @montesa_maria ➡️ EspA - @a_lois_ ➡️ LES, Sjögren, esclerodermia - @JesusLoarce ➡️ vasculitis, miopatías - @LuisCorTar ➡️ miscelánea
0
8
31
Systematic review/meta-analysis ➡️treatments for rheumatoid arthritis interstitial lung disease 💊 Methotrexate ⬇️ mortality, FVC and composite progression 💊 Abatacept⬇️ HRCT and composite progression 💊 RTX/MMF/JAKi stabilize FVC #rheumatology #RAILD
https://t.co/z6vcvBjweb
1
2
8
Update of the ATS/ERS Multidisciplinary Classification of the Interstitial Pneumonias🫁 ▶️Histological and radiological patterns (idiopathic, secondary) ▶️Interstitial vs alveolar ▶️New pattern (BIP), reclassification of old patterns (DIP➡️AMP, AIP➡️DAD) https://t.co/Xa4r2wP0EX
0
1
4
Two recent articles ➡️ lung trasplant results in patients with connective tissue disease associated interstitial lung disease #ILD: ▶️Observational study, Johns Hopkins Hospital cohort, focused in #myositis
https://t.co/mDT5m9FXuk ▶️Systematic review https://t.co/lr2yrPrWcW
pubmed.ncbi.nlm.nih.gov
The survival rate and the incidence of grade 3 PGD in CTD patients after lung transplantation are comparable to those of other patients undergoing lung transplantation for end-stage lung disease....
0
1
5
Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3
1
25
90
Subanalysis of the proDerm study: ▶️Predictors of response to IVIG: ⬆️cutaneous activity and anti-TIF1-γ➕ https://t.co/GVL3ipoaNE ▶️Efficacy of IVIG on systemic manifestations: 🔝Skeletal, also in pulmonary, gastrointestinal and constitutional domains https://t.co/oRjZDPB3O6
pubmed.ncbi.nlm.nih.gov
ClinicalTrials. gov identifier, NCT02728752.
0
0
1
Two recent studies on rheumatoid arthritis associated interstitial lung disease (RA-ILD): ▶️ Review of lung ultrasound as a screening tool in RA-ILD https://t.co/2GiBzsmdd1 ▶️ Peripheral biomarker signatures in RA-ILD: analysis of the VARA registry https://t.co/cu7IxMB3ct
pubmed.ncbi.nlm.nih.gov
Peripheral biomarker signatures are associated with RA-ILD and improve RA-ILD identification beyond clinical risk factors. In addition to demonstrating the potential for peripheral biomarkers to aid...
0
0
0
🎥¡Seguimos difundiendo el conocimiento! Ya puedes ver la ponencia: “¿Qué hago con mis úlceras y calcinosis?”, a cargo de la Sra. Patricia García, enfermera de @ReumatologiaRyC del Hospital Ramón y Cajal. 👉 https://t.co/uwOZcRw9bw
#aeecongreso2025 #Esclerodermia #Reumatología
0
5
10
Primera revisión sistemática de la literatura 📚 de @FragoulisGeorge et al. sobre la combinación de FAMEb en enfermedades inmunomediadas (¡1200 pacientes!). Combinaciones más frecuentes: TNFi+IL/23i, JAKi+bDMARDs, y vedolizumab+TNFi. Acceso abierto 🔑 https://t.co/0xYnp9YtSd
0
36
96
Nuestra enfermera Patricia García, habla del abordaje en la cura de las úlceras en pacientes con esclerosis sistémica. Fundamental el papel de la enfermera especializada en el cuidado de los pacientes.
#AEECONGRESO2025: PARTE 2 : Patricia García, enfermera de reumatología @ReumatologiaRyC y Dra.@MaykaFreire, del CHU Santiago de Compostela. Resumen completo de nuestro II Congreso Nacional de #esclerodermia para pacientes en:👇 https://t.co/nCwrqBcPnE
1
2
12
ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or
0
1
14
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). #EULAR2025 #OP0002
0
3
7
Neutrophils pivotal in #Behcet's syndrome pathogenesis↔️Target for therapy ▶️Infliximab superior to cyclophosphamide for induction ▶️Adalimumab superior to cyclosporin to reduce uveitis relapse via @RMD_clinic #EULAR2025
0
32
87
New systematic review by @sinisauksav et al. characterises the complete phenotypic spectrum of VEXAS syndrome. ➡️These findings will facilitate earlier diagnosis, inform monitoring strategies, and guide future research priorities. ➡️ https://t.co/YBEgKzWg4Z
0
31
84
Interesting work on the risk of progression of systemic sclerosis interstitial lung disease (ILD) ➡️ FVC decline in a 12 month period does not predict ILD progression in the next period ⚠️ Nevertheless, FVC decline is associated with mortality https://t.co/coSC3m8Fxa
pubmed.ncbi.nlm.nih.gov
For the German and Norwegian translations of the abstract see Supplementary Materials section.
0
2
7